What medications cause mastocytosis (Mast Cell Activation Disorder)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Medications do not typically cause mastocytosis, which is a rare disorder characterized by the abnormal accumulation of mast cells in one or more organ systems. Mastocytosis is generally considered a genetic or acquired condition rather than a medication-induced disorder. The condition is often associated with mutations in the KIT gene, particularly the D816V mutation, which leads to abnormal mast cell growth and accumulation. While medications don't cause mastocytosis, certain drugs can trigger mast cell degranulation in patients who already have mastocytosis, leading to symptom flares. These include:

  • NSAIDs like aspirin and ibuprofen
  • Opioid analgesics
  • Alcohol
  • Certain antibiotics (particularly vancomycin and fluoroquinolones)
  • Radiocontrast media
  • Some anesthetic agents, such as atracurium and mivacurium, which should be avoided in favor of safer alternatives like propofol, sevoflurane, or isoflurane 1. Patients with mastocytosis should maintain a list of medications that have previously caused reactions and discuss any new medications with their healthcare provider before taking them. Understanding these medication triggers is important for symptom management, though they are not causative factors for the underlying disease. In the event of anaphylaxis or other mast cell activation event, a full allergic workup should be initiated, including measurement of baseline serum tryptase level after full recovery, and identification of IgE-mediated hypersensitivity to drugs or latex requires detection of specific IgE and skin testing (skin prick and intradermal tests) 1. Pre-anesthetic treatment with anxiolytic agents, antihistamines, and possibly corticosteroids can help reduce the frequency and severity of mast cell activation events 1. It is essential to carefully review prior anesthetic records and identify/avoid known triggers of mast cell activation to prevent mast cell activation during and in the immediate aftermath of the surgical procedure 1.

From the Research

Medications that May Cause or Exacerbate Mastocytosis

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most common elicitors of drug-induced anaphylaxis (DIA) in patients with mastocytosis, accounting for 56% of cases 2
  • Perioperative agents and antibiotics can also trigger anaphylactic reactions in patients with mastocytosis, with frequencies of 23% and 13%, respectively 2
  • Certain tyrosine kinase inhibitors, such as imatinib, may be less effective or even ineffective against the KIT D816V mutant receptor, which is present in more than 90% of patients with typical indolent systemic mastocytosis (ISM) 3, 4, 5
  • Other medications that may be used to treat mastocytosis, such as midostaurin and avapritinib, can have unique and common adverse effects, and their use should be balanced against their toxicity and short- and long-term safety 3

Treatment Strategies for Mastocytosis

  • The mainstay of treatment for most categories of mastocytosis are H1 and H2 antihistamines, with the addition of corticosteroids for more severe symptoms 6
  • Symptomatic treatment may also comprise anti-leukotrienes, proton pump inhibitors, and topical corticosteroids 5
  • Cytoreductive therapy, including interferon alpha 2b and tyrosine kinase inhibitors, may be necessary for indolent mastocytosis with refractory symptoms, aggressive mastocytosis with organ dysfunction, and mast cell leukemia 4, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Drug-Induced Anaphylaxis Uncommon in Mastocytosis: Findings From Two Large Cohorts.

The journal of allergy and clinical immunology. In practice, 2024

Research

Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.

Immunology and allergy clinics of North America, 2018

Research

Treatment of systemic mast cell disorders.

Hematology/oncology clinics of North America, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.